PortfoliosLab logoPortfoliosLab logo
AVR vs. ABOS
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

AVR vs. ABOS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Anteris Technologies Global Corp (AVR) and Acumen Pharmaceuticals, Inc. (ABOS). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

AVR vs. ABOS - Yearly Performance Comparison


2026 (YTD)20252024
AVR
Anteris Technologies Global Corp
11.22%-10.57%-0.36%
ABOS
Acumen Pharmaceuticals, Inc.
11.85%22.67%-15.27%

Fundamentals

EPS

AVR:

-$5.98

ABOS:

-$2.00

Total Revenue (TTM)

AVR:

$1.91M

ABOS:

-$90.00K

Gross Profit (TTM)

AVR:

$1.34M

ABOS:

-$45.00K

EBITDA (TTM)

AVR:

-$63.54M

ABOS:

-$118.08M

Returns By Period

In the year-to-date period, AVR achieves a 11.22% return, which is significantly lower than ABOS's 11.85% return.


AVR

1D
8.61%
1M
-14.75%
YTD
11.22%
6M
23.33%
1Y
52.47%
3Y*
5Y*
10Y*

ABOS

1D
7.76%
1M
-24.84%
YTD
11.85%
6M
38.01%
1Y
114.55%
3Y*
-16.54%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Anteris Technologies Global Corp

Acumen Pharmaceuticals, Inc.

Return for Risk

AVR vs. ABOS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AVR
AVR Risk / Return Rank: 6262
Overall Rank
AVR Sharpe Ratio Rank: 5959
Sharpe Ratio Rank
AVR Sortino Ratio Rank: 6969
Sortino Ratio Rank
AVR Omega Ratio Rank: 6161
Omega Ratio Rank
AVR Calmar Ratio Rank: 6262
Calmar Ratio Rank
AVR Martin Ratio Rank: 5858
Martin Ratio Rank

ABOS
ABOS Risk / Return Rank: 8181
Overall Rank
ABOS Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
ABOS Sortino Ratio Rank: 8282
Sortino Ratio Rank
ABOS Omega Ratio Rank: 7474
Omega Ratio Rank
ABOS Calmar Ratio Rank: 8484
Calmar Ratio Rank
ABOS Martin Ratio Rank: 8383
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AVR vs. ABOS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Anteris Technologies Global Corp (AVR) and Acumen Pharmaceuticals, Inc. (ABOS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


AVRABOSDifference

Sharpe ratio

Return per unit of total volatility

0.52

1.27

-0.76

Sortino ratio

Return per unit of downside risk

1.60

2.21

-0.61

Omega ratio

Gain probability vs. loss probability

1.17

1.24

-0.08

Calmar ratio

Return relative to maximum drawdown

0.97

2.81

-1.84

Martin ratio

Return relative to average drawdown

1.83

6.96

-5.13

AVR vs. ABOS - Sharpe Ratio Comparison

The current AVR Sharpe Ratio is 0.52, which is lower than the ABOS Sharpe Ratio of 1.27. The chart below compares the historical Sharpe Ratios of AVR and ABOS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


AVRABOSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.52

1.27

-0.76

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.01

-0.37

+0.36

Correlation

The correlation between AVR and ABOS is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

AVR vs. ABOS - Dividend Comparison

Neither AVR nor ABOS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AVR vs. ABOS - Drawdown Comparison

The maximum AVR drawdown since its inception was -71.46%, smaller than the maximum ABOS drawdown of -95.56%. Use the drawdown chart below to compare losses from any high point for AVR and ABOS.


Loading graphics...

Drawdown Indicators


AVRABOSDifference

Max Drawdown

Largest peak-to-trough decline

-71.46%

-95.56%

+24.10%

Max Drawdown (1Y)

Largest decline over 1 year

-47.37%

-35.01%

-12.36%

Current Drawdown

Current decline from peak

-35.88%

-88.36%

+52.48%

Average Drawdown

Average peak-to-trough decline

-39.17%

-76.87%

+37.70%

Ulcer Index

Depth and duration of drawdowns from previous peaks

25.20%

14.13%

+11.07%

Volatility

AVR vs. ABOS - Volatility Comparison

The current volatility for Anteris Technologies Global Corp (AVR) is 17.57%, while Acumen Pharmaceuticals, Inc. (ABOS) has a volatility of 21.75%. This indicates that AVR experiences smaller price fluctuations and is considered to be less risky than ABOS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


AVRABOSDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.57%

21.75%

-4.18%

Volatility (6M)

Calculated over the trailing 6-month period

55.11%

65.71%

-10.60%

Volatility (1Y)

Calculated over the trailing 1-year period

101.97%

90.80%

+11.17%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

96.57%

98.32%

-1.75%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

96.57%

98.32%

-1.75%

Financials

AVR vs. ABOS - Financials Comparison

This section allows you to compare key financial metrics between Anteris Technologies Global Corp and Acumen Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00K400.00K600.00K800.00K1.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
310.00K
-90.00K
(AVR) Total Revenue
(ABOS) Total Revenue
Values in USD except per share items